These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
399 related articles for article (PubMed ID: 6451335)
21. The cutaneous infiltrates of leprosy: cellular characteristics and the predominant T-cell phenotypes. Van Voorhis WC; Kaplan G; Sarno EN; Horwitz MA; Steinman RM; Levis WR; Nogueira N; Hair LS; Gattass CR; Arrick BA; Cohn ZA N Engl J Med; 1982 Dec; 307(26):1593-7. PubMed ID: 6216407 [TBL] [Abstract][Full Text] [Related]
22. Mechanisms of T-cell unresponsiveness in leprosy. Bach MA; Hoffenbach A; Lagrange PH; Wallach D; Cottenot F Ann Immunol (Paris); 1983; 134D(1):75-84. PubMed ID: 6226239 [TBL] [Abstract][Full Text] [Related]
23. The accessory cell function of human alveolar macrophages in specific T cell proliferation. Toews GB; Vial WC; Dunn MM; Guzzetta P; Nunez G; Stastny P; Lipscomb MF J Immunol; 1984 Jan; 132(1):181-6. PubMed ID: 6228577 [TBL] [Abstract][Full Text] [Related]
24. T cell defect in lepromatous leprosy is reversible in vitro in the absence of exogenous growth factors. Mohagheghpour N; Gelber RR; Engleman EG J Immunol; 1987 Jan; 138(2):570-4. PubMed ID: 2947952 [TBL] [Abstract][Full Text] [Related]
25. Limiting dilution analysis of the human T cell response to mycobacterial antigens from BCG vaccinated individuals and leprosy patients. Brett SJ; Kingston AE; Colston MJ Clin Exp Immunol; 1987 Jun; 68(3):510-20. PubMed ID: 3308217 [TBL] [Abstract][Full Text] [Related]
26. In-vitro lymphoproliferative response to Mycobacterium leprae of HLA-D-identical siblings of lepromatous leprosy patients. Stoner GL; Touw J; Belehu A; Naafs B Lancet; 1978 Sep; 2(8089):543-7. PubMed ID: 79915 [TBL] [Abstract][Full Text] [Related]
27. Analysis of T-cell and B-cell responses to recombinant M. leprae antigens in leprosy patients and in healthy contacts: significant T-cell responses to antigens in M. leprae nonresponders. Thole JE; Janson AA; Kifle A; Howe RC; McLean K; Nurilygn A; Filley E; Shannon EJ; Bulla GJ; Hermans J Int J Lepr Other Mycobact Dis; 1995 Sep; 63(3):369-80. PubMed ID: 7594920 [TBL] [Abstract][Full Text] [Related]
28. Restoration of proliferative response to M. leprae antigens in lepromatous T cells against candidate antileprosy vaccines. Mustafa AS Int J Lepr Other Mycobact Dis; 1996 Sep; 64(3):257-67. PubMed ID: 8862259 [TBL] [Abstract][Full Text] [Related]
29. Suppressor T lymphocytes from lepromatous leprosy skin lesions. Modlin RL; Mehra V; Wong L; Fujimiya Y; Chang WC; Horwitz DA; Bloom BR; Rea TH; Pattengale PK J Immunol; 1986 Nov; 137(9):2831-4. PubMed ID: 2944966 [TBL] [Abstract][Full Text] [Related]
30. Low T lymphocyte responsiveness to Mycobacterium leprae antigens in association with HLA-DR3. van Eden W; Elferink BG; de Vries RR; Leiker DL; van Rood JJ Clin Exp Immunol; 1984 Jan; 55(1):140-8. PubMed ID: 6362932 [TBL] [Abstract][Full Text] [Related]
31. Lymphoproliferative responses of leprosy patients and healthy controls to nitrocellulose-bound M. leprae antigens. Sachdeva G; Kaur G; Bhutani LK; Bamezai RN Int J Lepr Other Mycobact Dis; 1999 Jun; 67(2):133-42. PubMed ID: 10472365 [TBL] [Abstract][Full Text] [Related]
32. Suppression of delayed hypersensitivity skin reactions to tuberculin by M. leprae antigens in patients with lepromatous and tuberculoid leprosy. Sengupta U; Sinha S; Ramu G; Lamb J; Ivanyi J Clin Exp Immunol; 1987 Apr; 68(1):58-64. PubMed ID: 3308210 [TBL] [Abstract][Full Text] [Related]
33. Reversal of T cell anergy in leprosy patients: in vitro presentation with Mycobacterium leprae antigens using murabutide and Trat peptide in liposomal delivery. Sridevi K; Khanna N; Chattree V; Pal PC; Haq W; Rao DN Int Immunopharmacol; 2003 Nov; 3(12):1589-600. PubMed ID: 14555284 [TBL] [Abstract][Full Text] [Related]
34. Expression of costimulatory molecules (CD80, CD86, CD28, CD152), accessory molecules (TCR alphabeta, TCR gammadelta) and T cell lineage molecules (CD4+, CD8+) in PBMC of leprosy patients using Mycobacterium leprae antigen (MLCWA) with murabutide and T cell peptide of Trat protein. Sridevi K; Neena K; Chitralekha KT; Arif AK; Tomar D; Rao DN Int Immunopharmacol; 2004 Jan; 4(1):1-14. PubMed ID: 14975355 [TBL] [Abstract][Full Text] [Related]
35. Alterations in T cell signal transduction by M. leprae antigens is associated with downregulation of second messengers PKC, calcium, calcineurin, MAPK and various transcription factors in leprosy patients. Chattree V; Khanna N; Rao DN Mol Immunol; 2007 Mar; 44(8):2066-77. PubMed ID: 17046060 [TBL] [Abstract][Full Text] [Related]
36. [The genetic susceptibility to leprosy in humans]. Lagrange PH; Abel L Acta Leprol; 1996; 10(1):11-27. PubMed ID: 8967289 [TBL] [Abstract][Full Text] [Related]
37. Mechanism of immunosuppression in leprosy: presence of suppressor factor(s) from macrophages of lepromatous patients. Salgame PR; Mahadevan PR; Antia NH Infect Immun; 1983 Jun; 40(3):1119-26. PubMed ID: 6221997 [TBL] [Abstract][Full Text] [Related]
38. In vitro studies on the effect of levamisole in lepromatous leprosy. Birdi TJ; Mistry NF; Mahadevan PR; Antia NH J Clin Lab Immunol; 1984 Feb; 13(2):93-6. PubMed ID: 6374154 [TBL] [Abstract][Full Text] [Related]